• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

What to Know About High Triglycerides
Discussions about heart health often center around blood pressure and cholesterol, with factors like poor sleep, smoking, family history of heart disease, and chronic stress thrown in. However, there’s one variable that doesn’t get covered as often, even though it can be an important indicator of cardiovascular risk: triglycerides. “We don’t really talk about triglycerides very much, especially compared to cholesterol, but they’re actually an essential part of understanding heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health in New York. “For some...
Source: TIME: Health - May 23, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news

The 5 Best Ways to Control High Cholesterol, According to People With the Condition
There are a variety of factors that influence cardiovascular risk—but cholesterol is one of the first things that doctors pay attention to. Having high levels of low-density lipoprotein (LDL) cholesterol is “definitely a variable we try to manage, because it’s been shown to be problematic for heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health. Though it’s often called the “bad” kind of cholesterol, LDL cholesterol makes up most of your body’s cholesterol stores. That means it’s not a villain on its own, but when levels start creeping ...
Source: TIME: Health - January 18, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news

Study Protocol and Baseline Characteristics of Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, The Combination of a Randomized Control Trial and an Observational Biomarker Study
CONCLUSIONS: After this study is completed, we will have further evidence on whether a highly purified EPA is effective in reducing cardiovascular events for secondary prevention or not, as well as whether if EPA/AA ratio is a predictor for future cardiovascular events.PMID:36372250 | DOI:10.1016/j.ahj.2022.11.008
Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Yuji Nishizaki Katsumi Miyauchi Hiroshi Iwata Teruo Inoue Atsushi Hirayama Kazuo Kimura Yukio Ozaki Toyoaki Murohara Kenji Ueshima Yoshihiro Kuwabara Sachiko Tanaka-Mizuno Naotake Yanagisawa Tosiya Sato Hiroyuki Daida Source Type: research

Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)
CONCLUSIONS: Among patients receiving statins, cardiovascular event incidence did not differ significantly between O3AEE-treated patients and non-O3AEE-treated patients. Further studies are required before definitive conclusions can be drawn on the effect of O3AEE on cardiovascular event incidence in high-risk patients with hypertriglyceridemia.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02285166.PMID:35772177 | DOI:10.1080/14740338.2022.2094914
Source: Expert Opinion on Drug Safety - June 30, 2022 Category: Drugs & Pharmacology Authors: Tamio Teramoto Hisao Ogawa Hirotsugu Ueshima Yasushi Okada Kazuo Haze Shigeyuki Matsui Keita Fujikawa Takamasa Hashimoto Sho Sakui Kunihiko Nishimura Mika Kajita Atsushi Horimoto Jovelle Fernandez Source Type: research

Do Omega-3 Fatty Acids Benefit Health?
An important clinical trial of omega-3 fatty acids in patients at high risk of cardiovascular disease is published in JAMA. In the STRENGTH trial (the Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia), 13  078 patients were randomized to receive 4 g/d of a carboxylic acid formulation of omega-3 fatty acids (a combination of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) or corn oil as a comparator. After a median follow-up of 42 months, there was no significant difference between the o mega-3 fatty acid group (6539 patients) a...
Source: JAMA - December 8, 2020 Category: General Medicine Source Type: research

Study: Fish Oil Doesn ’ t Seem To Prevent Heart Problems
This study is consistent with earlier trials. The US Food and Drug Administration approved the fish oil-based drug Vascepa for heart attack and stroke prevention in 2019. Nissen hopes the FDA will take a look at these studies and reconsider that decision. “But it’s hard to get something undone once the genie gets out of the bottle,” he said. An editorial in the journal that accompanies the study written by Dr. Gregory Curfman, assistant professor of medicine at Harvard Medical School, also suggested the FDA should require a postmarketing clinical trial of a high-dose of fish oil, such as Vascepa, vs. corn...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 16, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Health Syndicated CBSN Boston CNN fish oil Source Type: news

Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Purpose of review To discuss the current evidence regarding the relationship between omega-3 fatty acid intake and atherosclerotic cardiovascular disease (ASCVD) risk. Recent findings Combined results from randomized controlled trials using low-dosage (≤1.8 g/day of ethyl esters) eicosapentaenoic acid (EPA) or EPA + docosahexaenoic acid (DHA) suggest a small benefit for reducing coronary heart disease risk. The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) that administered 4 g/day icosapent ethyl (IPE) to individuals on statin at high or very high ASCVD risk with elevated triglyceri...
Source: Current Opinion in Cardiology - June 6, 2020 Category: Cardiology Tags: LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Anthony S. Wierzbicki Source Type: research

Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Authors: Bazarbashi N, Miller M Abstract INTRODUCTION: Icosapent Ethyl (IPE) is a highly purified (>96%) form of eicosapentanoic acid, a marine-derived omega-3 fatty acid known to reduce serum triglyceride levels. Experimental and human studies also support anti-atherosclerotic properties of IPE including antioxidant, anti-inflammatory, endothelial and plaque stabilizing effects. In the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)l),the addition of 4 grams IPE daily resulted in a 25% reduction in cardiovascular events beyond statins and other standard of care therapies. ...
Source: Expert Review of Cardiovascular Therapy - April 2, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Pages: 1  2